Novartis and the European Union

Novartis and the European Union (EU)

The team in Brussels is part of the Global Public Affairs business unit within Novartis and is based in the center of Brussels. The team represents the link between the Novartis Group and EU institutions as well as trade associations.

Listen, Learn and Take Action

We’re here to listen, to learn and to take action. We’re proud to have launched Novartis EU Connect and reimagine medicine with the EU policy community.

Follow Us on Twitter

Brussels Team

Rue Belliard 40
B-1040 Brussels

Meet the Team

Novartis commitment to COVID-19

Learn how Novartis is contributing to the global effort to combat the coronavirus (COVID-19) through research, and philanthropic aid.

Learn More

Novartis EU priorities

Learn more on our work to run the business smoothly

  • Accelerate access

    Accelerate Access

    We are committed to work with all stakeholders to develop collaborative and sustainable access solutions that address affordability concerns but more important, ensuring that patients have the right access to the right treatment.

  • Grandfather fishing with his granddaughters


    Cancer is a policy priority for Europe and a societal issue given its profound effect on patients, caregivers, family, health care systems and society. The EU beating cancer plan shows the strong commitment of the EU.

  • Novartis associates working in front of multiple screens

    Data and Digital

    We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. New technologies have the potential to improve applications that will improve patients’ lives.

  • Environmental Sustainability

    Environmental, social and governance

    Very ambitious targets are launched to be a leader in environmental sustainability in the healthcare industry, further strengthening its already ambitious target for carbon neutrality to include its entire supply chain by 2030.

  • Boy playing with a toy

    Orphan Medicinal Products & Pediatrics

    Our mission is to reimagine medicine to improve and extend people’s lives, including transformative medicines for rare disease patients and children in Europe and around the world.

  • Scientists working in a lab

    Security of supply

    Working closely with competent authorities to ensure all patients have timely access to high quality treatments and medicines. In order to achieve this policy priorities should be on security of supply, rather than on localization of manufacturing.

  • 38.8bn

    Euros of GDP contribution in Europe

  • 218 000

    jobs created on the European market

  • -700m

    Euros of reduced environmental impact

  • 76.5bn

    Euros of social impact coming from our products

Trade associations



    Stands for European Federation of Pharmaceutical Industries and Associations representing biopharmaceutical industry operating in Europe. EFPIA has a direct membership of 36 national associations and 39 leading pharmaceutical companies.

  • Eucope


    Is Europe's trade body for innovative companies working in the field of pharmaceuticals and medical technologies who are active in research, development of pharmaceuticals, biotechnologies and medical devices.

  • EuropaBio


    The European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. They represent 78 corporate, associate members and bioregions & 15 national biotechnology associations representing over 1800 biotech SMEs.

  • MedicinesforEurope


    Represents the European generic, biosimilar and valued added pharmaceutical industries. Their members’ portfolio covers 80% of therapy areas, and in so doing, safeguards the sustainability of Europe’s healthcare systems for future generations.